Steady-State Mobilization of Peripheral Blood Progenitor Cells by Cytokines Alone in Patients with Solid Tumors or Hematological Malignancies

Kröger, Nicolaus; Zeller, W.; Hassan, Hamisa Jane; Krüger, William; Renges, Helmut; Rüssmann, B; Fuchs, Nina V.; Rauhöft, C.; Gutensohn, K.; Löliger, C; Erttmann, R; Kühnl, P.; Zander, A.R.

doi:10.1159/000053469

Cited by 3 publications

(3 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The outcome was similar to that obtained by Madura et al [5], who reported that 72 patients survived with a mean of 5.7 months, regardless of whether they underwent radical PD. However, table 4 presents the characteristics of the patients with ASC of the pancreas who survived longer than12 months [2, 7,23,24,25]. Most of these patients were males (6/7, 85.7%) with tumors located in the pancreatic head (5/7, 71.4%).…”

Section: Discussionmentioning

confidence: 99%

Adenosquamous Carcinoma of the Pancreas

Hsu¹,

Yeh²,

Chen

et al. 2005

Digestion

View full text Add to dashboard Cite

Background/Aims: Adenosquamous carcinoma (ASC) of the pancreas is rare and correct preoperative diagnosis is difficult. Case reports of ASC of the pancreas are sporadic and have typically employed small series. This study investigated the clinicopathological features of 7 cases of ASC of the pancreas and reviewed the pertinent literature to elucidate this rare disease. Methodology: Seven patients (4 men and 3 women; age range 38–79 years; median 66 years) with ASC of the pancreas who underwent surgical treatment at Chang Gung Memorial Hospital between February 1993 and April 2000 were retrospectively reviewed. Results: Symptoms of ASC were as follows: abdominal pain (85.7%), body weight loss (85.7%), jaundice (42.9%) and anorexia (42.9%). The tumors were located at the head of the pancreas in 4 patients (57.1%), at the body in 2, and at the tail in 2. One patient had ASC at the body and tail. Most cases (5/7, 71.4%) were anemic. Seven (100%) and 5 patients (71.4%) had elevated serum CEA and CA19-9 levels, respectively. Curative pancreaticoduodenectomy was performed on 2 patients, bypass surgery on 3, and exploratory laparotomy on 2. Two patients underwent intraoperative radiotherapy. Three patients received postoperative adjuvant chemotherapy. No surgical mortality or morbidity occurred. Five of 7 patients (71.4%) died within 6 months after surgery. The median survival of the 7 patients was 4.41 months (range 1.12–22.42). Conclusions: Patients with ASC present symptoms similar to those of adenocarcinoma of the pancreas. Most patients had dismal prognosis despite aggressive surgery with or without adjuvant therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Adenosquamous Carcinoma of the Pancreas

Hsu¹,

Yeh²,

Chen

et al. 2005

Digestion

View full text Add to dashboard Cite

show abstract

“…Squamous differentiation in primary pancreatic ACA has long been associated with poor survival in clinical series [1,5,6,10,14,15,16,17], case reports [3,7,18,19,20,21,22,23,24,25,26,27,28,29,30], a meta-analysis [31], and a tumor registry study [32]. Thus, growing evidence has unequivocally shown that squamous features seen in a resection specimen portend poor prognosis so should be reported even if they are focal [6].…”

Section: Discussionmentioning

confidence: 99%

The Differential Diagnosis of Squamous Cells in Pancreatic Aspirates: From Contamination to Adenosquamous Carcinoma

Olson

Siddiqui

Ali³

2013

Acta Cytologica

View full text Add to dashboard Cite

Background: This study was conducted to describe the frequency and significance of squamous cells in fine needle aspiration (FNA) specimens of the pancreas in benign and malignant processes. Methods: A retrospective review was performed of 102 patients with squamous cells in their pancreatic FNA specimens from 1986 to 2012. The malignant cases were classified as adenosquamous carcinoma (ASqC) or metastatic squamous cell carcinoma, and a double institutional review of the ASqC cases was undertaken to characterize the clinical and pathological features and survival statistics of patients who present with unresectable or metastatic ASqC and have no follow-up surgery. Survival analyses were performed. Results: Of the 4,094 pancreas FNA procedures performed in the study, squamous features were found in 102 (2.5%) of all cases, and 48% of these cases represented ASqC. The other cases were contamination (52%) or atypical (<1%). ASqC constituted 4.5% (46/1,025) of all primary pancreatic exocrine malignancies. When compared with conventional adenocarcinoma, ASqC demonstrated a significantly poorer overall median survival (11.0 vs. 6.51 months; p = 0.023), and this difference was also seen in patients presenting with metastatic disease (median survival of 9.1 vs. 4.2 months; p = 0.025). Conclusions: Squamous cells in FNA specimens from the pancreas have a broad differential diagnosis that ranges from contamination to ASqC.

show abstract

“…0,05% im peripheren Blut. Nach Verabreichung von hämatopoetischen Wachstumsfaktoren wie G-CSF steigt die Konzentration von CD34+-Zellen im peripheren Blut an Tag 4 und 5 um den Faktor 100 an, sodass die Stammzellsammlung mittels Leukapherese zwischen Tag 4 und 6 durchgeführt werden kann (Kröger et al 1999).…”

Section: Stammzellquelleunclassified

Klinische und histologische Prognosefaktoren für Patienten mit rezidivierten / refraktären aggressiven B-Zell-Lymphomen nach allogener Stammzelltransplantation

Christian¹

View full text Add to dashboard Cite

Steady-State Mobilization of Peripheral Blood Progenitor Cells by Cytokines Alone in Patients with Solid Tumors or Hematological Malignancies

Cited by 3 publications

References 36 publications

Adenosquamous Carcinoma of the Pancreas

Adenosquamous Carcinoma of the Pancreas

The Differential Diagnosis of Squamous Cells in Pancreatic Aspirates: From Contamination to Adenosquamous Carcinoma

Klinische und histologische Prognosefaktoren für Patienten mit rezidivierten / refraktären aggressiven B-Zell-Lymphomen nach allogener Stammzelltransplantation

Contact Info

Product

Resources

About